We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

19 hedge funds and large institutions have $17M invested in Milestone Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

21.16% less ownership

Funds ownership: 58.8% → 37.64% (-21%)

24% less funds holding

Funds holding: 25 → 19 (-6)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

93% less capital invested

Capital invested by funds: $231M → $17M (-$214M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
19
Holders Change
-6
Holders Change %
-24%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
3
Reduced
9
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RI
RTW Investments
New York
+$6.18M
2
Millennium Management
Millennium Management
New York
+$2.81M
3
SFM
Sphera Funds Management
Israel
+$1.18M
4
UBS Group
UBS Group
Switzerland
+$234K
5
BlackRock
BlackRock
New York
+$201K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12.2M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.61M
3
TCM
Tekla Capital Management
Massachusetts
-$9.23M
4
ACP
Acuta Capital Partners
California
-$8.14M
5
NHAS
Novo Holdings A/S
Denmark
-$6.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$7.94M +$6.18M +356,838 +9%
NHAS
2
Novo Holdings A/S
Denmark
$3.83M -$6.13M -353,885 -15%
BC
3
Boxer Capital
California
$2.03M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$1.08M -$12.2M -701,892 -55%
Invesco
5
Invesco
Georgia
$589K -$35.6K -2,056 -0.6%
TCM
6
Tekla Capital Management
Massachusetts
$392K -$9.23M -533,343 -71%
GTC
7
Ghost Tree Capital
New York
$384K -$455K -26,267 -11%
Millennium Management
8
Millennium Management
New York
$353K +$2.81M +162,364 +550%
SFM
9
Sphera Funds Management
Israel
$125K +$1.18M +67,992 New
Morgan Stanley
10
Morgan Stanley
New York
$83K -$26.5K -1,533 -3%
PM
11
Prosight Management
Texas
$77K +$53.9K +3,111 +8%
TD Asset Management
12
TD Asset Management
Ontario, Canada
$42K -$229K -13,200 -36%
UBS Group
13
UBS Group
Switzerland
$25K +$234K +13,499 New
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$23.9K -$173K -10,015 -44%
BlackRock
15
BlackRock
New York
$21K +$201K +11,616 New
Renaissance Technologies
16
Renaissance Technologies
New York
$19K +$177K +10,242 New
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
– -$9.61M -600,000 Closed
ACP
18
Acuta Capital Partners
California
– -$8.14M -508,500 Closed
O
19
OrbiMed
New York
– -$5.83M -364,206 Closed
Fidelity Investments
20
Fidelity Investments
Massachusetts
– -$3.84M -239,600 Closed
ZP
21
Zimmer Partners
New York
– -$2.56M -160,000 Closed
PCM
22
Pentwater Capital Management
Florida
– -$512K -32,000 Closed
OAM
23
Oxford Asset Management
United Kingdom
– -$316K -19,715 Closed
Barclays
24
Barclays
United Kingdom
– -$14.7K -851 -95%
TRCT
25
Tower Research Capital (TRC)
New York
– -$2K -142 Closed

MIST Hedge Fund Activity: Q1 2020 in Review

19 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2020, worth a combined $17M — down 93% from $231M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MIST and 4 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was RTW Investments, adding an estimated $6.18M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.2M.

  • 19 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2020, down from 25 in Q4 2019.
  • Funds reported $17M of Milestone Pharmaceuticals stock for Q1 2020, down 93% quarter-over-quarter.
  • 4 funds opened new Milestone Pharmaceuticals positions in Q1 2020 and 8 closed out, a net change of -4 holders.
  • The largest Milestone Pharmaceuticals buyer in Q1 2020 was RTW Investments, an estimated $6.18M added.
  • The largest Milestone Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $12.2M sold.

Based on aggregated 13F filings for Q1 2020.